Irritable bowel syndrome and biliary tract pathology. Clinical analysis

Irritable bowel syndrome (IBS) – a recurrent functional disorder of the gastrointestinal tract (GIT), the main symptom of which is abdominal pain necessarily associated with a change in intestinal function. IBS is a functional intestinal disorder in which recurrent abdominal pain is associated with a defecation act and a change in the frequency or shape of the stool. The diagnosis of IBS remains exclusively clinical. The difficulty in studying IBS, especially from the perspective of its epidemiology, is that there is still no universal and specific biological marker. Very often patients complain about symptoms typical for several functional disorders, in particular, biliary tract pathology and IBS. The article discusses the multi-component causes and mechanisms of IBS formation, which are also present in other functional gastrointestinal tract diseases. Patients with IBS often have functional disorders of the biliary tract (FDBT) that are not associated with organic pathology. There are no reliable differences in the frequency and nature of FDBT in patients with IBS, depending on its current variant - with constipation or diarrhea prevalence. As a result, the treatment of patients with IBS remains a challenge, and the recurrence of the disease depends on the state of psycho-emotional health, the presence of overlap syndrome in most cases. The article presents the main international criteria for diagnostics of IBS. The main approaches to the treatment of IBS are considered. Good results in the treatment of IBS are observed when using drugs that affect the complex of pathophysiological mechanisms of the disease. This is confirmed in the article by a clinical case study. The prescription of the Sparex drug for pain relief in a patient with IBS and FDBT is justified by the fact that it not only eliminates pain, but also improves the rheological properties of bile, typical for overlap “IBS-FDBT” syndrome.

1. Maev I.V., Bordin D.S., Eremina E.U., Ilchishina T.A., Kaibysheva V.O., Osipenko M.F. et al. Irritable Bowel Syndrome. Modern Aspects Of Epidemiology, Pathogenesis And Treatment (a review). Ehksperimentalnaya i klinicheskaya gastroehnterologiya = Experimental and Clinical Gastroenterology. 2018;158(10):68–73. (In Russ.) doi: 10.31146/1682-8658-ecg-158-10-68-73.

2. Samsonov A.A., Semenova A.V., Andreyev D.N., Goncharenko A.Yu., Lobanova E.G., Kuznetsova E.I. Overlap syndrome of functional dispepsia and irritable bowel syndrome: up-to-date state of the problem. Farmateka = Pharmateca. 2018;(2):13–17. (In Russ.) doi: 10.18565/pharmateca.2018.2.13-17.

3. Drossman D.A., Hasler W.L. Rome IV – Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. doi: 10.1053/j.gastro.2016.03.035.

4. Maev I.V., Cheremushkin S.V., Kucheryavyy Yu.A. Irritable bowel syndrome. Rome IV criteria. On the role of visceral hypersensitivity and methods of correction. Мoscow; 2016. 64 p. (In Russ.)

5. Morozova M.A., Rupchev G.Y., Alekseyev A.A., Beniashvili A.G., Mayevskaya M.V., Poluektova Y.A. et al. Dysphoric spectrum of emotional disorders at irritable bowel syndrome. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):12–22. (In Russ.) doi: 10.22416/1382-4376-2017-27-1-12-22.

6. Canavan C., West J., Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80. doi: 10.2147/CLEP.S40245.

7. Lovell R.M., Ford A.C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. doi: 10.1016/j.cgh.2012.02.029.

8. Hunt R., Quigley E., Abbas Z., Eliakim A., Emmanuel A., Goh K.-L. et al. Coping with common GI symptoms in the community: A Global Perspective on Heartburn, Constipation, Bloating, and Abdominal Pain/Discomfort. World Gastroenterology Organization; 2013. 137 p. Available at: https://www.worldgastroenterology.org/guidelines/global-guidelines/common-gisymptoms/common-gi-symptoms-english.

9. Osipenko M.F., ButGusaim V.I., Voloshina N.B., Bicbulatova E.A. “Overlap syndrome” irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Sibirskiy meditsinskiy zhurnal (Irkutsk) = Siberian Medical Journal (Irkutsk). 2008;(5):21–26. (In Russ.) Available at: https://elibrary.ru/item.asp?id=11684136.

10. McNally M.A., Locke G.R., Zinsmeister A.R., Schleck C.D., Peterson J., Talley N.J. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334–343. doi: 10.1111/j.1365-2036.2008.03715.x.

11. Maev I.V., Cheryomushkin S.V., Kucheryavy Yu.A., Cheryomushkina N.V. Algorithm for managing patients with irritable bowel syndrome. Roman criteria IV. RMZh = RMJ. 2017;25(10):718–722. (In Russ.) Available at: https://www.rmj.ru/articles/gastroenterologiya/Algoritm_vedeniya_pacientov_s_sindromom_razdraghennogo_kishechnika_Rimskie_kriterii_IV.

12. Behar J., Corazziari E., Guelrud M., Hogan W., Sherman S., Toouli J. Functional gall bladder and sphincter of oddi disorders. Gastroenterology. 2006;130(5):1498–1509. doi: 10.1053/j.gastro.2005.11.063.

13. Polunina T.Ye. Perspective trends and opportunities in the treatment of patients with irritable bowel syndrome. Terapiya = Therapy. 2016;(2):27–35. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/32934.

14. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K., Belousova Y.A., Beniashvili A.G., Vasilyev S.V. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Сoloproctology. 2017;27(5):76–93. (In Russ.) doi: 10.22416/1382-4376-2017-27-5-76-93.

15. Corazziari E.S., Cotton P.B. Gallbladder and Sphincter of Oddi Disorders. Am J Gastroenterol. 2010;105(4):764–769. doi: 10.1038/ajg.2010.67.

16. Polunina T.E. Biliary dysfunction. Rome consensus IV. Terapiya = Therapy. 2017;(6):16–28. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/35489.

17. Mansueto P., Seidita A., D’Alcamo A., Carroccio A. Non-celiac gluten sensitivity: literature review. J Am Coll Nutr. 2014;33(1):39–54. doi: 10.1080/07315724.2014.869996.

18. Ford A.C., Moayyedi P., Lacy B.E., Lembo A.J, Saito Y.A., Schiller L.R. et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:2–26. doi: 10.1038/ajg.2014.187.

19. Brandt L.J., Chey W.D., Foxx-Orenstein A.E., Schiller L.R., Schoenfeld P.S., Spiegel B.M. et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(S1):1–35. doi: 10.1038/ajg.2008.122.

20. Chey W.D., Maneerattaporn M., Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver. 2011;5(3):253–266. doi: 10.5009/gnl.2011.5.3.253.

21. Daly J., Bergin A., Sun W.M., Read N.W. Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions. Gut. 1993;34(6):799– 802. doi: 10.1136/gut.34.6.799.

22. Den Hertog A., Van den Akker J. The action of mebeverine and metabolites on mammalian non-myelinated nerve fibres. Eur J Pharmacol. 1987;139(3):353–355. doi: 10.1016/0014-2999(87)90594-2.

23. Agafonova N.A., Yakovenko E.P., Yakovenko A.V., Ivanov A.N. Biliary sludge and its treatment. Lechebnoe delo = Medicine. 2016;(3):14–20. (In Russ.) Available at: https://elibrary.ru/item.asp?id=27327540.